WO2003076391A2 - Hemmstoffe der urokinase, ihre herstellung und verwendung - Google Patents
Hemmstoffe der urokinase, ihre herstellung und verwendung Download PDFInfo
- Publication number
- WO2003076391A2 WO2003076391A2 PCT/EP2003/002489 EP0302489W WO03076391A2 WO 2003076391 A2 WO2003076391 A2 WO 2003076391A2 EP 0302489 W EP0302489 W EP 0302489W WO 03076391 A2 WO03076391 A2 WO 03076391A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radical
- amidino
- compound according
- dser
- carbon atoms
- Prior art date
Links
- 0 CO*OC(NCCCC[C@@](C(NCc(cc1)ccc1C(N)=N)=O)NC([C@@](CCO)NSCc1ccccc1)=O)=O Chemical compound CO*OC(NCCCC[C@@](C(NCc(cc1)ccc1C(N)=N)=O)NC([C@@](CCO)NSCc1ccccc1)=O)=O 0.000 description 1
- HUWYECOXBXPFCK-OTWWCFJSSA-N NC(c1ccc(CNC([C@H](CCCCNC(CCC(NCCOCCOCCNC(CCC(NCCCC[C@@H](C(NCc(cc2)ccc2C(N)=N)=O)NC(C(C2)(C2O)NSCc2ccccc2)=O)=O)=O)=O)=O)NC([C@@H](CO)NS(Cc2ccccc2)(=O)=O)=O)=O)cc1)=N Chemical compound NC(c1ccc(CNC([C@H](CCCCNC(CCC(NCCOCCOCCNC(CCC(NCCCC[C@@H](C(NCc(cc2)ccc2C(N)=N)=O)NC(C(C2)(C2O)NSCc2ccccc2)=O)=O)=O)=O)=O)NC([C@@H](CO)NS(Cc2ccccc2)(=O)=O)=O)=O)cc1)=N HUWYECOXBXPFCK-OTWWCFJSSA-N 0.000 description 1
- HTJDAPVSHYZITN-LEWJYISDSA-N NCCCC[C@@H](C(NCc(cc1)ccc1C(N)=N)=O)NC([C@@H](CO)NSCc1ccccc1)=O Chemical compound NCCCC[C@@H](C(NCc(cc1)ccc1C(N)=N)=O)NC([C@@H](CO)NSCc1ccccc1)=O HTJDAPVSHYZITN-LEWJYISDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- C07K5/06069—Ser-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to new urokinase inhibitors, their production and use for therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases.
- uPA plasminogen activator urokinase
- uPA uPA receptor
- PAI-1 and PAI-2 J.-F. Cajot et al., Proc. Natl. Acad. Sei. USA 87, 6939- 6943, 1990; M. Baker et al., Cancer Res. 50, 4876-4684, 1990.
- PAI-1 and PAI-2 J.-F. Cajot et al., Proc. Natl. Acad. Sei. USA 87, 6939- 6943, 1990; M. Baker et al., Cancer Res. 50, 4876-4684, 1990.
- PAI-1 and PAI-2 J.-F. Cajot et al., Proc. Natl. Acad. Sei. USA 87, 6939- 6943, 1990; M. Baker et al., Cancer Res. 50, 4876-4684, 1990.
- PAI-1 and PAI-2 J.-F. Cajot et al., Proc. Natl. Aca
- the benzothiophene derivatives are very specific, their inhibitory effect on plasmin and the plasminogen activator of the tissue type (tPA) is low, but the synthesis of compounds of this type is very complex.
- N ⁇ -triisopropylphenylsulfonyl-3-amidinophenylalanine derivatives reach micromolar Kj values (0.41 ⁇ M for the most effective compound), but are very unspecific uPA inhibitors; trypsin, thrombin and plasmin are inhibited with the same or a stronger effect (J Sturzbecher et al., Bioorg. Med. Letters 9, 3147-3152, 1999).
- Very effective uPA inhibitors are disclosed in WO 99/05096 and WO 01/81314 with further developed ⁇ -naphthamidines. There are five IC; o values in the nanomolar range, but not yet declared the selectivity and biological activity.
- EP 18 32 71 discloses lysine derivatives which have a certain uPA inhibition but also inhibit other comparable enzymes and are therefore only very specifically or to a limited extent usable for medical purposes.
- uPA inhibitors described low molecular weight polypeptides (approx. 50 amino acids) which are derived from natural inhibitors. Their in vivo use is severely restricted due to their peptide character and the molecular size.
- Recently peptidyl aldehydes were reported in WO 00/05245 which contained an arginal at the C-terminal and a D-serine in P3 and very effectively inhibited uPA.
- WO 02/14349 describes further non-covalently binding urokinase inhibitors which, in addition to the acylated amidinobenzylamines already described in WO 01/96286, have, for example, acylated guanidinobenzylamine, 2-amidino-5-aminomethylthiophene and other arginine mimetics as the Pl radical.
- the invention is therefore based on the object of specifying an active ingredient which is also suitable for therapeutic applications and which inhibits urokinase with high activity and which circulates in the body for as long as possible after IV or SC administration.
- the letter P stands in connection with a subscript 1 or 2, ie Pi or P 2 , for amino acid residues and their derivatives as constituents of structure A in formula I of the present invention.
- the substituted or unsubstituted natural or unnatural amino acid Pi in structure A corresponds to Schechter and Berger in the L configuration and the substituted or unsubstituted natural or unnatural amino acid P in structure A in structure A corresponds to P3 according to Schechter and Berger.
- Rg is a branched or unbranched alkyl radical having preferably 1 to 6 C atoms, in particular 1 to 3 C atoms, especially ethyl;
- R 2 is an H, a branched or unbranched alkyl radical having 1 to 8 carbon atoms, preferably having 1 to 3 carbon atoms, or
- R 8 is H or a branched or unbranched alkyl radical with preferably 1 to 6 C atoms, in particular 1 to 3
- Carbon atoms especially ethyl, or
- U is a phenyl or cyclohexyl radical or a heterophenyl or heterocyclohexyl radical with preferably at least one N, S or O as hetero atom, in particular pyridine, piperidine or pyrimidine;
- X is N or CH, preferably CH;
- Z occurs in the 3- or 4-position and is an aminomethyl, a guanidino or an amidino group
- R 4 is H, OH, NH 2 , -COR 15 or -COOR 5
- R 15 is a branched or unbranched alkyl radical having 1 to 16, preferably 1 to 8, in particular 1 to 4, especially 1 to 2 C Is atoms or a substituted or unsubstituted aryl or heteroaryl, aralkyl or heteroaralkyl radical
- the alkyl radical preferably having 1 to 16, in particular 1 to 8, especially 1 to 4 and particularly preferably 1 to 2, carbon atoms
- the aryl or Heteroaryl radical preferably has 4 to 14, in particular 6 to 10, especially 6 C atoms and preferably 1 to 3 N as hetero atom;
- one or more charged residues are preferably derived from -COOH, -CH (COOH) 2 , -SO 2 H, NH 2 , an amidino, hydroxyamidmo, amidrazone or guanidino group in the residues Ri, R 2 , R 3 or R 5 are present; Also preferred is a compound of general formula I in the form of a prodrug or in the form of its salt.
- a prodrug in the sense of the present invention is an acylated amidino- or guamdobenzylamine according to the general formula I, which is present as a pharmaceutically inactive derivative of the corresponding pharmaceutically active substance and, after oral administration, is spontaneously or enzymatically biotransformed with release of the pharmaceutically active substance.
- inhibitors of urokinase which are eliminated particularly slowly, are 4-amidinobenzylamine derivatives according to the general formula I, an additional addition being an oligo- or polyalkylene glycol chain functionalized with an amino or carboxyl group, in particular a poly- or oligoethylene glycol or poly - or oligopropylene glycol chain is coupled directly to a functional group of R, in particular via an -NH or a -CO group, forming an amide bond to R 2 , the oligo- or polyalkylene glycol chain having at least at both ends a functional group, in particular a substituted or has unsubstituted amino and or carboxyl group, or wherein the oligo- or polyalkylene glycol chain has at least at one end a functional group, in particular a substituted or unsubstituted amino and / or carboxyl group and at the other end as alkyl ether with 1-4 C atoms, in particular as methyl ether > where R 2
- Two molecules of the general formula I can be coupled to an oligo- or polyalkylene glycol chain which has at least at both ends a functional group, in particular a substituted or unsubstituted amino and or carboxyl group. If the derivatives of 4-amidinobenzylamine according to the invention are coupled with an oligo- or polyalkylene glycol chain, Pl in structure A of general formula I preferably has the following general formula II:
- a particular advantage of oligo- and / or polyalkylene glycol derivatives of the urokinase inhibitors according to the invention is their prolonged half-life in the circulation after systemic administration.
- Such particularly suitable compounds are compounds of the general formula I, where U at 1, 2 or 3 positions preferably with a halogen, in particular fluorine or chlorine, or a methyl, ethyl, propyl, methoxy, ethoxy or propoxy radical is substituted.
- Other particularly suitable compounds are compounds of the general formulas I, where a carboxyl group is protected as an ester, preferably as an ethyl ester.
- R 9 and / or R ⁇ in this case is an alkylcarbonyl, aralkylcarbonyl, alkyloxycarbonyl or aralkyloxycarbonyl radical
- the linear or branched alkyl radical preferably has 1 to 6, in particular 1 to 4, carbon atoms
- the aryl radical preferably has 5 to 8, in particular 6, carbon atoms.
- amidinobenzylamide radical the amidino group is in the 4-position and P 2 is derived from the amino acid D-Ser and Pi is derived from glycine, alanine, serine, aspartic acid or glutamic acid and R 5 an unsubstituted or provided with a carboxyl group aryl or aralkylsulfonyl radical with 1 to 16, preferably 1 to 8, in particular 1 to 4, especially 1 to 2, carbon atoms in the alkyl radical and 6 to 14, preferably 6 to 10, in particular 6 C atoms in the aryl radical.
- Suitable compounds are compounds of the general formulas I or II, the substituent on the substituted aryl, heteroaryl, aralkyl or heteroaralkyl radical being a halogen, preferably fluorine, chlorine or bromine, in particular fluorine or chlorine.
- R is COOH or COOMe in ortho, meta or para or H and X are the same
- R is 4-COOH or 3-COOH with X is CH and Ri is H, CH 3 or CH 2 -OH; or
- R is 4-C ⁇ with X is CH and Ri is CH 3 ;
- R is 4- ( ⁇ H 2 -CH 2 ) with X is CH and R- is H; or
- R is H with X is CH and Ri is H, CH 2 -OH, CH 2 -O (Bzl), CH 2 -NH 2 ,
- R is 4-COOMe with X is CH and Ri is CH 2 -OH; or R is 4-CL, 4-Me, 4-F or 3,4-Di-Cl with X is CH and i is H; or R is H with X is N and Ri is H.
- PEG is a polyethylene glycol 5 ooo having an average molecular weight of 5000 Da, it being possible as polyethylene glycol chains having an average molecular weight of 100 - 20,000 Da can be used; or
- a particularly preferred inhibitor of urokinase with high affinity which is also eliminated particularly slowly, forms acylated 4-amidinobenzylamine which, as the Pi (P2) amino acid, is a natural or artificial, unsubstituted or substituted basic amino acid in the L configuration, particularly preferably arginine or Lysine has, and when D-serine is bound as a P 2 (P3) residue, and when the compound has an N-terminal protective group R 5 from an aryl or aralkyl-sufonyl residue.
- acylated 4-amidinobenzylamine which, as the Pi (P2) amino acid, is a natural or artificial, unsubstituted or substituted basic amino acid in the L configuration, particularly preferably arginine or Lysine has, and when D-serine is bound as a P 2 (P3) residue, and when the compound has an N-terminal protective group R 5 from an aryl or aralkyl-sufonyl residue.
- Benzylsulfonyl-dSer-cis-Cha (4-NH 2 ) -4-amidinobenzylamide Benzylsulfonyl-dSer-trans-Cha (4-NH 2 ) -4-Amidinobenzylamide Benzylsulfonyl-dSer-cis-homoCha (4-NH 2 ) -4- Amidinobenzylamide Benzylsulfonyl-dSer-trans-homoCha (4-NH 2 ) -4- Amidinobenzylamide Benzylsulfonyl-dSer-trans-Cha (4-CH 2 NH 2 ) -4- Amidinobenzylamide
- the compounds are generally in the form of salts, preferably with mineral acids, preferably as hydrochlorides, or preferably as salts with suitable organic acids.
- Preferred salts of mineral acids are also sulfates.
- Suitable organic acids are, for example, acetic acid, formic acid, methylsulfonic acid, succinic acid, malic acid or trifluoroacetic acid, preferred salts of organic acids being acetates.
- the compounds of the general formula I can be prepared in a manner known in principle, as described below, for example as follows:
- the Boc-protected 4-acetyloxamidinobenzylamine is obtained from the commercially available 4-cyanobenzylamine (Showa Denko, Japan) by methods known to those skilled in the art (Judkins et al., Synth. Commun. 26, 4351 (1996)).
- the Boc protective group After the Boc protective group has been split off, the further amino acids and the protective group R 5 are coupled on using standard coupling methods with Boc as the N-terminal protective group.
- the P 2 (P3) amino acid can also be coupled directly as an N-aryl- or N-aralkyl-sulfonyl-protected amino acid.
- the peptide analogs are built up sequentially starting from acetyloxamidinobenzylamm. Most intermediate products crystallize well and are easy to clean. The final cleaning of the inhibitors takes place in the last stage, preferably via preparative, reversed-phase HPLC.
- the present invention also relates to a process for the preparation of a compound of the general formula I or II, the corresponding amino acids being coupled sequentially to a 4-acetyloxamidinobenzylamine, the N-terminal amino acid either already carrying the R 5 radical or subsequently carrying it is bound.
- the invention further relates to a medicament containing an inhibitor according to the invention and further pharmaceutically suitable auxiliaries and / or additives.
- auxiliaries and / or additives which serve, for example, to stabilize and / or preserve the medicament are generally familiar to the person skilled in the art (for example Sucker H. et al., (1991) Pharmaceutical Technology, 2nd edition, Georg Thieme Verlag, Stuttgart) , These include, for example, physiological saline solutions, Ringer's dextrose, Ringer's lactate, demineralized water, stabilizers, antioxidants, complexing agents, antimicrobial compounds, proteinase inhibitors and / or inert gases.
- the medicament could be used, for example, in parenteral use form, in particular in intraartial, intravenous, intramuscular or subcutaneous form, in enteral use form, in particular for oral or rectal use, or in topical use form, in particular as a dermatical. Intravenous or subcutaneous applications are preferred.
- the medicament is administered, for example, in the form of a tablet, a dragée, a capsule, a pellet, suppository, a solution, in particular a solution for injection or infusion, eye, nose and ear drops, a juice, a capsule, one Emulsion or suspension, a globule, styli, aerosol, powder, a paste, cream or ointment.
- the urokinase inhibitors according to the invention or the drugs mentioned are preferably used for diagnosis, therapy or prophylaxis of a tumor, in particular for reducing the formation of tumor metastases, preferably in oral, subcutaneous, intravenous or transdermal form.
- Analytical HPLC Shimadzu LC-10A system, column: Vydac C I8 , 5 ⁇ m (250 x 4 mm) solvent A: 0.1% TFA in water, B: 0.1% TFA in ACN, gradient: 10% B bis 60% B in 50 min, 1 ml / min flow, detection at 220 or 215 ⁇ m.
- Preparative HPLC Shimadzu LC-8A system, column: Knauer C ⁇ 8 , 5 ⁇ m (250 x 32 mm) solvent A: 0.1% TFA in water, B: 0.1% TFA in ACN, gradient: 10% B bis 55% B in 120 min, 10 ml / min flow, detection at 220 nm.
- Mass spectroscopy The mass spectra were measured on a compact probe from Kratos (Manchester, England) with a time-of-flight measurement detector and ⁇ -cyano-hydroxycinnamic acid as a matrix, or on an ESI-MS LCQ from Finnigan (Bremen, Germany).
- Boc-Glu (OBzl) -OH (Orpegen, Heidelberg) was coupled to 4-acetyloxamidinobenzylamine x HCl according to Frerot et al. (Tetrahedron 47, 259 ff, 1991).
- 2.27 g (9.3 mmol) of 4-acetyloxamidinobenzylamine x HCl and 3.138 gg (9.3 mmol) of Boc-Glu (OBzl) -OH were dissolved in approx. 25 ml of DMF.
- 4.84 g (9.3 mmol) of PyBOP and 3.888 ml (27.9 mmol) of TEA were added and the pH was adjusted to 9 with TEA.
- H-Glu (OBzl) -4-acetyloxamidinobenzylamide x HCl 4.1 g of Boc-Glu (Bzl) -4-acetyloxamidinobenzylamide were dissolved in 100 ml of 1N HCl in glacial acetic acid and left to stand at room temperature for 45 min. Then it was largely evaporated down and precipitated with dry diethyl ether, then stripped off and the product washed again with fresh ether. After drying the product iV, it was used for the synthesis according to point lg) without further purification.
- Example 2 Inhibition of urokinase by selected amidinobenzylamide compounds
- Example 3 Elimination after IV administration of 1 mg / kg body weight in the rat of derivatives of benzylsulfonyl-D-Ser-Gly-4-amidino-benzylamide with Ala or Glu in the P2 position
- Plasma level ( ⁇ g / ml)
- mice Female Wistar rats (240-300 g body weight) were anesthetized (ethyl urethane 2.5 g / ml in NaCl, 0.5 ml / 100 g rat), followed by Preparation of the carotid artery located on the neck. A catheter fixed in this vessel made it possible to take blood at fixed times. The application volume was 0.5 ml, 0.9% NaCl was used as the application solution.
- Blood samples of 500 ⁇ l were taken at the following times: 2, 5, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 and 270 min , The resulting blood loss was compensated for immediately after taking the sample with 500 ⁇ l 0.9% NaCl solution.
- Citrate plasma was obtained by centrifuging the blood at 1200 * g for 10 min. The concentration of the active substances in the plasma was determined by means of HPLC.
- the solvent was removed in vacuo, the residue was dissolved in water (brought to pH 8.5-9 with 1N NaOH) and extracted twice with ether.
- the aqueous phase was acidified with 5% KHSO solution and extracted 3 times with ethyl acetate.
- the combined ethyl acetate phase was washed 3 ⁇ with 5% KHSO 4 solution and NaCl-saturated solution and dried with Na 2 SO 4 .
- the solvent was then removed in vacuo.
- Boc-Ser (Bzl) -4-acetyloxamidinobenzylamide 4.847 g (16.41 mmol) Boc-Ser (Bzl) -OH were dissolved in 50 ml THF and at -15 ° C with 1.805 ml (16.41 mmol) NMM and 2.133 ml of CKBIE. The mixture was stirred at -15 ° C. for 10 min, then 4 g (16.41 mmol) of 4- (acetyloxamidino) benzylamine ⁇ HCl (prepared as described in WO 01/96286 A2) and again 1.805 ml (16.41 mmol ) NMM added.
- the mixture was stirred for a further hour at -15 ° C and overnight at room temperature.
- the solvent was removed in vacuo, the mixture was taken up in ethyl acetate and washed 3 ⁇ with 5% KHSO 4 , NaCl-saturated water, saturated NaHCO 3 solution and again with NaCl-saturated water and dried with Na 2 SO 4 .
- the solvent was removed in vacuo and the product crystallized from ethyl acetate.
- the mixture was stirred for a further 15 min with ice cooling and then for a further 3 h at room temperature.
- the solvent was removed in vacuo, the residue was dissolved in water (brought to pH 8.5-9 with 1N NaOH) and extracted twice with ether.
- the aqueous phase was then acidified with 5% KHSO 4 solution and extracted 3 ⁇ with ethyl acetate.
- the combined ethyl acetate phase was washed 3 ⁇ with 5% KHSO 4 solution and NaCl-saturated solution and dried with Na 2 SO 4 .
- the solvent was removed in vacuo.
- the DMF was concentrated in vacuo, the remaining residue was dissolved in ethyl acetate and washed 3 ⁇ with 5% KHSO 4 , NaCl-saturated water, saturated NaHCO 3 solution and again with NaCl-saturated water and dried with Na 2 SO 4 .
- the solvent was removed in vacuo. The crude product was used for the next synthesis step without further purification.
- the solvent was removed in vacuo, the mixture was taken up in ethyl acetate and washed 3 ⁇ with 5% KHSO 4 , NaCl-saturated water, saturated NaHCO 3 solution and again with NaCl-saturated water and dried with Na 2 SO 4 .
- the solvent was removed in vacuo and the product crystallized from ethyl acetate.
- Boc-Arg (Boc) 2 -OH was dissolved in 25 ml THF and at -15 ° C with 122 ⁇ l (1.11 mmol) NMM and 137 ⁇ l (1.05 mmol) CKIBE offset. The mixture was stirred at -15 ° C. for 10 min, then 0.274 g (1.11 mmol) of 4- (acetyloxamidino) benzylamine ⁇ HCl (prepared as described in WO 01/96286 A2) and again 122 ⁇ l (1.11 mmol ) NMM added. The mixture was stirred for a further hour at -15 ° C and overnight at room temperature.
- the solvent was removed in vacuo, the mixture was taken up in ethyl acetate and washed 3 ⁇ with 5% KHSO 4 , NaCl-saturated water, saturated NaHCO 3 solution and again with NaCl-saturated water and dried with Na 2 SO 4 .
- the solvent was removed in vacuo, the product being obtained as a white, amorphous substance.
- Table 3 Hem constants (Kj in ⁇ M) and half-lives (b / . In h) of elimination (ß-phase) in rats after intravenous administration of 1 mg / kg for inhibitors of the general structure.
- the constants inhibition constants (Kj and t> / 2 ) were determined for uPA as described in Stzbecher et al., (1997) Vol. 40, 3091-3099 and for plasmin, trypsin and thrombin analogously to this.
- the precipitated product was filtered off and washed on the frit with plenty of isopropanol and then with diethyl ether.
- the crude product (approx. 1 g) was dried in vacuo xmd cleaned with an ion exchanger.
- the crude product was dissolved in water and applied to a column (5 cm ⁇ 20 cm, Fractogel EMD COO-, equilibrated with water).
- the column was first washed with 1000 ml of water and then the product was eluted with 2 mM ammonium acetate solution.
- the product-containing fractions (HPLC control, elution at 44.96% B) were combined and the water was partially concentrated.
- the product was lyophilized 3 times in total from water. Yield: 590 mg, HPLC: 44.96% B
- Example 10 Bzls-dSer-Lys (CO-CH 2 -O-CH 2 -CO-NH-CH 2 -CH 2 -
- the compound is synthesized using standard methods known to those skilled in the art.
- the inhibition constants are as follows:
- the compound is synthesized using standard methods known to those skilled in the art.
- the inhibition constants are as follows:
- the compound is synthesized using standard methods known to those skilled in the art.
- the inhibition constants are as follows:
- Example 14 Inhibition of metastasis in the animal model
- mice The influence of the inhibitor benzylsulfonyl-dSer-Ser-4-amidinobenzylamide on the metastasis was investigated in female mice (strain CD1 nu / nu, approx. 25 g body weight, Charles River, Sulzfeld).
- the mice were 106 cells from a lacZ-labeled human fibrosarcoma cell line (HT1080 AN PKZ12 K15-1, dissolved in 200 ul PBS) i.v. applied (Krüger et al., Cancer Metastasis Rev. 1998-99, 17, 285-294 and Krüger et al, Oncogene 1998, 16, 2419-2423).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003219039A AU2003219039A1 (en) | 2002-03-11 | 2003-03-11 | Urokinase inhibitors, production and use thereof |
DE50310038T DE50310038D1 (de) | 2002-03-11 | 2003-03-11 | Hemmstoffe der urokinase, ihre herstellung und verwendung |
EP03714803A EP1485345B1 (de) | 2002-03-11 | 2003-03-11 | Hemmstoffe der urokinase, ihre herstellung und verwendung |
US10/506,579 US7838560B2 (en) | 2002-03-11 | 2003-03-11 | Urokinase inhibitors, production and use thereof |
CA2478409A CA2478409C (en) | 2002-03-11 | 2003-03-11 | Inhibitors of urokinase, their preparation and use |
JP2003574613A JP4898091B2 (ja) | 2002-03-11 | 2003-03-11 | ウロキナーゼの阻害剤、それらの製造および使用 |
DK03714803T DK1485345T3 (da) | 2002-03-11 | 2003-03-11 | Urokinaseinhibitorer, deres fremstilling og anvendelse |
US12/951,835 US8476306B2 (en) | 2002-03-11 | 2010-11-22 | Urokinase inhibitors, production and use thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2002110592 DE10210592A1 (de) | 2002-03-11 | 2002-03-11 | Hemmstoffe der Urokinase, ihre Herstellung und Verwendung |
DE10210592.8 | 2002-03-11 | ||
DE10245059.5 | 2002-09-26 | ||
DE10245059 | 2002-09-26 | ||
DE10261435.0 | 2002-12-28 | ||
DE10261435 | 2002-12-28 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/506,579 A-371-Of-International US7838560B2 (en) | 2002-03-11 | 2003-03-11 | Urokinase inhibitors, production and use thereof |
US10506579 A-371-Of-International | 2003-03-11 | ||
US12/951,835 Continuation US8476306B2 (en) | 2002-03-11 | 2010-11-22 | Urokinase inhibitors, production and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003076391A2 true WO2003076391A2 (de) | 2003-09-18 |
WO2003076391A3 WO2003076391A3 (de) | 2004-01-22 |
Family
ID=27808239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/002489 WO2003076391A2 (de) | 2002-03-11 | 2003-03-11 | Hemmstoffe der urokinase, ihre herstellung und verwendung |
Country Status (9)
Country | Link |
---|---|
US (2) | US7838560B2 (de) |
EP (1) | EP1485345B1 (de) |
JP (1) | JP4898091B2 (de) |
AT (1) | ATE399175T1 (de) |
AU (1) | AU2003219039A1 (de) |
CA (1) | CA2478409C (de) |
DE (1) | DE50310038D1 (de) |
DK (1) | DK1485345T3 (de) |
WO (1) | WO2003076391A2 (de) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004062657A1 (de) * | 2003-01-15 | 2004-07-29 | Curacyte Chemistry Gmbh | Acylierten 4-amidino- und 4-guanidinobenzylaminen zur inhibierung von plasmakallikrein |
WO2006032461A1 (de) * | 2004-09-21 | 2006-03-30 | Wilex Ag | Stabile dosierungsform von phenylalanin-derivaten |
EP1711825A2 (de) * | 2004-01-07 | 2006-10-18 | Ambit Biosciences Corporation | Konjugierte kleine moleküle |
WO2009026949A1 (en) * | 2007-08-31 | 2009-03-05 | Dsm Ip Assets B.V. | 4-amidino benzylamines for cosmetic and/or dermatological use |
EP2087885A1 (de) | 2005-06-24 | 2009-08-12 | Wilex AG | Verwendung von Urokinasehemmern zur Behandlung und/oder Prävention von neuropathologischen Erkrankungen |
WO2010149459A1 (de) * | 2009-05-27 | 2010-12-29 | Philipps-Universität Marburg | Verwendung von hemmstoffen der hat und tmprss2 als arzneimittel |
WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
WO2014009862A2 (en) | 2012-07-12 | 2014-01-16 | Dsm Ip Assets B.V. | Cosmetic composition comprising benzylsulfonyl-d-ser-homophe-(4-amidino-benzylamide) and a polyalcohol |
EP2960232A1 (de) | 2014-06-25 | 2015-12-30 | DSM IP Assets B.V. | Verfahren zur Herstellung eines Dipeptidderivats |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10342108A1 (de) | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
DE102005044319A1 (de) * | 2005-09-16 | 2007-03-22 | Curacyte Chemistry Gmbh | 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa |
DE102006050672A1 (de) * | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
CA2822350A1 (en) | 2010-12-21 | 2012-06-28 | The Medicines Company (Leipzig) Gmbh | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa |
RU2015148536A (ru) * | 2013-04-12 | 2017-05-18 | Торэй Индастриз, Инк. | Антитромботический искусственный кровеносный сосуд |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10029014A1 (de) * | 2000-06-15 | 2001-12-20 | Univ Schiller Jena | Urokinase-Hemmstoffe |
WO2002014349A2 (en) * | 2000-08-11 | 2002-02-21 | Corvas International, Inc. | Non-covalent inhibitors of urokinase and blood vessel formation |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3577700D1 (de) | 1984-11-30 | 1990-06-21 | Shosuke Okamoto | Lysinderivat und proteinase-inhibitor. |
US5518735A (en) | 1990-11-15 | 1996-05-21 | Pentapharm Ag | Meta-substituted phenylalanine derivatives |
DE4243858A1 (de) | 1992-12-23 | 1994-06-30 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
CA2133761A1 (en) | 1993-02-10 | 1994-08-18 | Jorg Sturzebecher | Piperazides of substituted phenylalanine derivates as thrombin inhibitors |
SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
US5550213A (en) | 1993-12-27 | 1996-08-27 | Rutgers, The State University Of New Jersey | Inhibitors of urokinase plasminogen activator |
AU1025795A (en) | 1994-01-27 | 1995-08-03 | Mitsubishi Chemical Corporation | Prolineamide derivatives |
US5705487A (en) | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
US5726159A (en) | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
ZA951617B (en) | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
US5707966A (en) | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
JP3655632B2 (ja) | 1994-04-26 | 2005-06-02 | アベンティス・ファーマスーティカルズ・インコーポレイテッド | 第Xa因子インヒビター |
EA199700186A1 (ru) | 1995-02-17 | 1998-02-26 | Басф Акциенгезельшафт | Новые дипептидные амидины, используемые в качестве ингибиторов тромбина |
US5710130A (en) | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
US5914319A (en) | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
CH689611A5 (de) | 1995-03-01 | 1999-07-15 | Pentapharm Ag | Urokinase-Inhibitoren. |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
AR005245A1 (es) | 1995-12-21 | 1999-04-28 | Astrazeneca Ab | Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion |
US5863929A (en) | 1996-06-25 | 1999-01-26 | Eli Lilly And Company | Anticoagulant agents |
ZA986594B (en) | 1997-07-25 | 1999-01-27 | Abbott Lab | Urokinase inhibitors |
NZ506507A (en) * | 1998-02-09 | 2003-08-29 | Dimensional Pharm Inc | Heteroaryl amidine, methylamidine or guanidine derivatives useful as urokinase inhibitors |
ATE230599T1 (de) | 1998-07-20 | 2003-01-15 | Wilex Ag | Neue urokinase-inhibitoren |
US7342018B2 (en) | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
US6576613B1 (en) | 1998-07-24 | 2003-06-10 | Corvas International, Inc. | Title inhibitors of urokinase |
GB9816228D0 (en) * | 1998-07-24 | 1998-09-23 | Pfizer Ltd | Isoquinolines |
SE9802974D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
DE59806475D1 (de) | 1998-09-18 | 2003-01-09 | Pentapharm Ag Basel | Urokinase-inhibitoren |
CA2356934A1 (en) | 1999-01-13 | 2000-07-20 | Genentech, Inc. | Serine protease inhibitors |
FR2791683A1 (fr) | 1999-03-30 | 2000-10-06 | Synthelabo | Derives de n-sulfonyl-dipeptides, leur preparation et leur application en therapeutique |
GB9908410D0 (en) * | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
AR023510A1 (es) | 1999-04-21 | 2002-09-04 | Astrazeneca Ab | Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina. |
DE19940389A1 (de) | 1999-08-25 | 2001-03-01 | Wilex Biotechnology Gmbh | Selektive Inhibitoren des Urokinase-Plasminogen Aktivators |
US6797504B1 (en) | 2000-09-08 | 2004-09-28 | Dendreon San Diego Llc | Inhibitors of serine protease activity of matriptase or MTSP1 |
DE10005631A1 (de) | 2000-02-09 | 2001-08-23 | Max Planck Gesellschaft | Arginin-Mimetika als Faktor X¶a¶-Inhibitoren |
DE10013715A1 (de) | 2000-03-20 | 2001-09-27 | Wilex Biotechnology Gmbh | Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators |
WO2001081314A1 (en) | 2000-04-25 | 2001-11-01 | Abbott Laboratories | Naphthamidine urokinase inhibitors |
DE10029015A1 (de) | 2000-06-15 | 2001-12-20 | Curacyte Ag | Hemmstoffe für den Gerinnungsfaktor Xa |
WO2001097794A2 (en) | 2000-06-21 | 2001-12-27 | Georgetown University | Inhibitors of matriptase for the treatment of cancer |
AU2002222933A1 (en) | 2000-07-13 | 2002-01-30 | Millennium Pharamaceuticals, Inc. | Inhibitors of factor xa |
ES2285989T3 (es) | 2000-08-11 | 2007-12-01 | Wilex Ag | Inhibidores no covalentes de la uroquinasa y de la formacion de vasos sanguineos. |
AU2002230836A1 (en) | 2000-12-18 | 2002-07-01 | Merck & Co., Inc. | Benzylamine derivatives and their use as thrombin inhibitors |
DE10102878A1 (de) | 2001-01-23 | 2002-08-01 | Haemosys Gmbh | Oligo- oder Polyalkylengekoppelte Thrombininhibitoren |
US7001887B2 (en) | 2001-02-02 | 2006-02-21 | Chugai Seiyaku Kabushiki Kaisha | Peptide derivatives |
DE50209313D1 (de) | 2001-12-12 | 2007-03-08 | Wilex Ag | Selektive arylguanidinpeptide als urokinaseinhibitoren |
WO2003070229A2 (de) | 2002-02-22 | 2003-08-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verwendung von proteinaseinhibitoren zur behandlung von autoimmunerkrankungen |
DE10210590A1 (de) | 2002-03-11 | 2003-10-02 | Curacyte Ag | Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
DE10212555A1 (de) | 2002-03-15 | 2003-09-25 | Univ Schiller Jena | Verwendung von Hemmstoffen des Gerinnungsfaktors Xa als Wirkstoffe zur Erkennung und Unterdrückung des Wachstums maligner Tumore sowie der von diesen ausgehenden Metastasierung |
DE10225876A1 (de) | 2002-06-11 | 2003-12-24 | Wilex Ag | Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren |
WO2004031216A1 (de) | 2002-10-04 | 2004-04-15 | Pentapharm Ag | Substrate für tafi (a) |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
DE10322191B4 (de) | 2003-05-16 | 2014-02-27 | The Medicines Company (Leipzig) Gmbh | N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
DE10323898A1 (de) | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
DE10342108A1 (de) | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
DE102005044319A1 (de) | 2005-09-16 | 2007-03-22 | Curacyte Chemistry Gmbh | 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
-
2003
- 2003-03-11 AU AU2003219039A patent/AU2003219039A1/en not_active Abandoned
- 2003-03-11 DE DE50310038T patent/DE50310038D1/de not_active Expired - Lifetime
- 2003-03-11 DK DK03714803T patent/DK1485345T3/da active
- 2003-03-11 WO PCT/EP2003/002489 patent/WO2003076391A2/de active IP Right Grant
- 2003-03-11 JP JP2003574613A patent/JP4898091B2/ja not_active Expired - Fee Related
- 2003-03-11 EP EP03714803A patent/EP1485345B1/de not_active Expired - Lifetime
- 2003-03-11 US US10/506,579 patent/US7838560B2/en not_active Expired - Fee Related
- 2003-03-11 CA CA2478409A patent/CA2478409C/en not_active Expired - Fee Related
- 2003-03-11 AT AT03714803T patent/ATE399175T1/de active
-
2010
- 2010-11-22 US US12/951,835 patent/US8476306B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10029014A1 (de) * | 2000-06-15 | 2001-12-20 | Univ Schiller Jena | Urokinase-Hemmstoffe |
WO2002014349A2 (en) * | 2000-08-11 | 2002-02-21 | Corvas International, Inc. | Non-covalent inhibitors of urokinase and blood vessel formation |
Non-Patent Citations (2)
Title |
---|
KÜNZEL S ET AL: "4-Amidinobenzylamine-Based Inhibitors of Urokinase" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, Bd. 12, Nr. 4, 25. Februar 2002 (2002-02-25), Seiten 645-648, XP002193207 ISSN: 0960-894X in der Anmeldung erwähnt * |
ZESLAWSKA E ET AL.: "Crystals of Urokinase Type Plasminogen Activator Complexes Reveal the Binding Mode of Peptidomimetic Inhibitors" JOURNAL OF MOLECULAR BIOLOGY, Bd. 328, Nr. 1, 18. April 2003 (2003-04-18), Seiten 109-118, XP002253026 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10301300B4 (de) * | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
EP2340822A1 (de) * | 2003-01-15 | 2011-07-06 | The Medicines Company (Leipzig) GmbH | Acylierte 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
WO2004062657A1 (de) * | 2003-01-15 | 2004-07-29 | Curacyte Chemistry Gmbh | Acylierten 4-amidino- und 4-guanidinobenzylaminen zur inhibierung von plasmakallikrein |
EP1711825A2 (de) * | 2004-01-07 | 2006-10-18 | Ambit Biosciences Corporation | Konjugierte kleine moleküle |
EP1711825A4 (de) * | 2004-01-07 | 2008-01-23 | Ambit Biosciences Corp | Konjugierte kleine moleküle |
AU2005287582B2 (en) * | 2004-09-21 | 2010-08-19 | Wilex Ag | Stable dosing form of phenylalanine derivatives |
JP2008513529A (ja) * | 2004-09-21 | 2008-05-01 | ヴィレックス アクチェンゲゼルシャフト | フェニルアラニン誘導体の安定な投与形 |
WO2006032461A1 (de) * | 2004-09-21 | 2006-03-30 | Wilex Ag | Stabile dosierungsform von phenylalanin-derivaten |
CN1993144B (zh) * | 2004-09-21 | 2012-05-30 | 威丽克斯股份公司 | 苯丙氨酸衍生物的稳定剂型 |
EP2087885A1 (de) | 2005-06-24 | 2009-08-12 | Wilex AG | Verwendung von Urokinasehemmern zur Behandlung und/oder Prävention von neuropathologischen Erkrankungen |
WO2009026949A1 (en) * | 2007-08-31 | 2009-03-05 | Dsm Ip Assets B.V. | 4-amidino benzylamines for cosmetic and/or dermatological use |
WO2010149459A1 (de) * | 2009-05-27 | 2010-12-29 | Philipps-Universität Marburg | Verwendung von hemmstoffen der hat und tmprss2 als arzneimittel |
WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
WO2014009862A2 (en) | 2012-07-12 | 2014-01-16 | Dsm Ip Assets B.V. | Cosmetic composition comprising benzylsulfonyl-d-ser-homophe-(4-amidino-benzylamide) and a polyalcohol |
WO2014009862A3 (en) * | 2012-07-12 | 2015-03-26 | Dsm Ip Assets B.V. | Cosmetic composition comprising benzylsulfonyl-d-ser-homophe-(4-amidino-benzylamide) and a polyalcohol |
EP2960232A1 (de) | 2014-06-25 | 2015-12-30 | DSM IP Assets B.V. | Verfahren zur Herstellung eines Dipeptidderivats |
Also Published As
Publication number | Publication date |
---|---|
CA2478409C (en) | 2012-07-31 |
JP2005526762A (ja) | 2005-09-08 |
DK1485345T3 (da) | 2008-11-03 |
EP1485345A2 (de) | 2004-12-15 |
US20110065799A1 (en) | 2011-03-17 |
WO2003076391A3 (de) | 2004-01-22 |
US7838560B2 (en) | 2010-11-23 |
EP1485345B1 (de) | 2008-06-25 |
DE50310038D1 (de) | 2008-08-07 |
US20050176993A1 (en) | 2005-08-11 |
US8476306B2 (en) | 2013-07-02 |
CA2478409A1 (en) | 2003-09-18 |
JP4898091B2 (ja) | 2012-03-14 |
AU2003219039A1 (en) | 2003-09-22 |
ATE399175T1 (de) | 2008-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1583526B1 (de) | Acylierte 4-amidino- und 4-guanidinobenzylaminen zur inhibierung von plasmakallikrein | |
DE69528528T2 (de) | Thrombin-inhibitoren | |
EP0871653B1 (de) | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
US8476306B2 (en) | Urokinase inhibitors, production and use thereof | |
DE60209227T2 (de) | 2-((n-(2-amino-3-(heteroaryl- oder -aryl)propionyl)aminoacyl)amino)-alkylboronsäurederivate | |
EP1294742B1 (de) | Urokinase-hemmstoffe | |
WO1995030687A1 (de) | Neurokinin (tachykinin)-antagonisten | |
DE3207311A1 (de) | Neue n-acylpolypeptide und ihre herstellung | |
DD217807A5 (de) | Verfahren zur herstellung neuer substituierter tetrapeptide | |
EP0374097A2 (de) | Verwendung von Peptidisosteren als retrovirale Proteasehemmer | |
DE69431359T2 (de) | Prolyl-endopeptidaseinhibitoren | |
EP0374098A2 (de) | Retrovirale Proteasehemmer | |
EP1483285B1 (de) | HEMMSTOFFE DES GERINNUNGSFAKTORS Xa, IHRE HERSTELLUNG UND VERWENDUNG | |
EP1664089B1 (de) | Basisch-substituierte benzylaminanaloga als inhibitoren des gerinnungsfaktors xa, ihre herstellung und verwendung | |
DE3328952A1 (de) | Neue polypeptide, verfahren zu ihrer herstellung, pharmazeutische praeparate welche sie enthalten, sowie ihre verwendung | |
DE69519182T2 (de) | Azapeptid-Derivate | |
DE69606552T2 (de) | Acylierte enolderivate von alpha-ketoestern und alpha-ketoamiden | |
WO1997019953A2 (de) | Neue lh-rh-antagonisten mit verbesserter wirkung | |
DE10210592A1 (de) | Hemmstoffe der Urokinase, ihre Herstellung und Verwendung | |
DE4445939A1 (de) | Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen (II) | |
DE3839128A1 (de) | Renin-hemmende dipeptide, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2478409 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003219039 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003574613 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003714803 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003714803 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10506579 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003714803 Country of ref document: EP |